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Abstract
Introduction: Bone marrow transplantation (BMT) is a complex process regulated by different cytokines and growth factors.
The pleiotropic cytokine IL-6 (Interleukin-6) and related cytokines of the same family acting on the common signal
transducer gp130 are known to play a key role in bone marrow (BM) engraftment. In contrast, the exact signalling events
that control IL-6/gp130-driven haematopoietic stem cell development during BMT remain unresolved.
Methods: Conditional gp130 knockout and knockin mice were used to delete gp130 expression (gp130
DMx), or to selectively
disrupt gp130-dependent Ras (gp130
DMxRas) or STAT signalling (gp130
DMxSTAT) in BM cells. BM derived from the respective
strains was transplanted into irradiated wildtype hosts and repopulation of various haematopoietic lineages was monitored
by flow cytometry.
Results: BM derived from gp130 deficient donor mice (gp130
DMx) displayed a delayed engraftment, as evidenced by
reduced total white blood cells (WBC), marked thrombocytopenia and anaemia in the early phase after BMT. Lineage
analysis unravelled a restricted development of CD4(+) and CD8(+) T-cells, CD19(+) B-cells and CD11b(+) myeloid cells after
transplantation of gp130-deficient BM grafts. To further delineate the two major gp130-induced signalling cascades, Ras-
MAPK and STAT1/3-signalling respectively, we used gp130
DMxRas and gp130
DMxSTAT donor BM. BMT of gp130
DMxSTAT cells
significantly impaired engraftment of CD4(+), CD8(+), CD19(+) and CD11b(+) cells, whereas gp130
DMxRas BM displayed
a selective impairment in early thrombopoiesis. Importantly, gp130-STAT1/3 signalling deficiency in BM grafts severely
impaired survival of transplanted mice, thus demonstrating a pivotal role for this pathway in BM graft survival and function.
Conclusion: Our data unravel a vital function of IL-6/gp130-STAT1/3 signals for BM engraftment and haematopoiesis, as well
as for host survival after transplantation. STAT1/3 and ras-dependent pathways thereby exert distinct functions on
individual bone-marrow-lineages.
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Introduction
IL-6 type cytokines, especially IL-6, IL-11, OSM (oncostatin M)
and LIF (leukaemia inhibitory factor) in conjunction with their
shared common receptor subunit gp130 (glycoprotein 130) play an
important role for the regulation of organism homeostasis [1].
Gp130 thereby acts as the membrane bound part of the receptor
complex, that upon homo- or hetero-dimerization induces the
phosphorylation of its intracellular tyrosines [2] activating Ras-o r
STAT1/3- dependent signalling cascades. The general impor-
tance of gp130 and dependent processes becomes evident already
during the phase of embryonic development. Gp130 knockout
embryos suffer from a severely restricted haematopoiesis as well as
from an impaired hepatic development and subsequently die in
utero [3]. This functionally distinguishes gp130 from its multiple
ligands, which show redundant biological functions. Therefore, the
phenotype of individual cytokine-knockout mice is often more
subtle and less severe than deletion of their receptors.
Introduction of conditional gp130-knockout mice by Betz et al
[3] provided initial insights into the regulatory role of gp130 in
haematopoiesis. Those mice showed a spontaneous mild throm-
bocytopenia, while leukocyte numbers were increased. The
relative amount of T-cells was also reduced. After the induction
of chemically induced BM injury those mice showed a delayed
recovery in erythrocytes and platelets together with a 40%
reduction of haematopoietic progenitors. Another study demon-
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of haematopoietic stem cells [4].
In contrast, mice overexpressing the gp130 ligands IL-6 or LIF
displayed a hyperproliferation of haematopoietic cells and de-
veloped splenomegaly, plasmocytosis, thrombocytosis and extra-
medullar haematopoiesis [5]. It was shown that IL-6 and LIF
synergize with IL-3 and stem cell factor (SCF), which are
important for the integrity of haematopoietic progenitor cells [6].
In an effort to delineate the dichotomy of gp130-dependent
intracellular signalling, that leads to the activation of Ras-o r
STAT-pathways respectively, partial gp130- knockin/knockout
mice were created [7]. Mice lacking the 4 distal tyrosine residues of
the cytoplasmic domain of gp130, which constitute the STAT1/3
binding sites, showed elevated numbers of BM precursors and
reduced platelet counts [8]. On the contrary, mice carrying a point
mutation in gp130 tyrosine-757 display elevated basal STAT3
activation but are deficient for gp130-Ras-signalling [9]. These
mice develop a broad spectrum of haematopoietic abnormalities,
including splenomegaly, lymphadenopathy, and thrombocytosis
[10].
Whereas the role of gp130-signals in steady state haematopoiesis
has been well characterized, its functions in BMT remain unclear.
There is evidence, that gp130 is important in endothelial cells of
BM recipient mice [11], yet the more pressing issue, whether it
plays a role within the donor cell compartment is still unresolved.
This is especially important since donor cells could be easily
analysed and conditioned prior to transplantation. This prompted
us to carefully dissect the function of gp130 in BM donor cells
during the process of engraftment and proliferation.
We have recently demonstrated the contribution of the different
gp130-dependent signalling pathways for the maintenance of
hepatocyte integrity during liver regeneration and fibrosis de-
velopment [12]. Here, we identify gp130-STAT1/3 as a vital




Mice were housed in 12-hour light/dark cycles, with free access
to food and water and were treated in accordance with the criteria
of the German administrative panel on laboratory animal care and
approved by the local Animal Care Committee (Landesamt fu ¨r
Natur, Umwelt und Verbraucherschutz Nordrhein-Westfalen,
LANUV, NRW, PF 101052, 45610 Recklinghausen, Germany,
AZ: 9.93.2.10.35.07.155).
At least 5 animals were analysed per time point. All experiments
were repeated at least three times.
C57/BL6/J mice carrying loxP sites flanking exon 16 coding for
the gp130 transmembrane domain were crossed with transgenic
(tg) mice expressing Cre-recombinase as described previously
[3,13]. Type-I Interferon (IFN)-sensible Mx1 promotor (MxCre)
controlled cre-recombinase expression [3]. This was activated by
intraperitoneal injection of 100 mg of poly (I: C) (Sigma-Aldrich)
10 and 5 days before the start of the experiment. IFNc-induced
activation of the Mx1 promoter led to the expression of Cre and
subsequent deletion of gp130-exon 16. Animals that were negative
for the Cre-allele but carried loxP sites in both gp130 alleles
(gp130
loxP/loxP) served as controls and were treated equally.
BM chimeric mice were generated by transplanting freshly
isolated BM from GFP transgenic (b-actin/GFP) donors. Wildtype
(gp130
loxP/loxP) or gp130 knockout (gp130
DMx) animals were both
injected with poly (I: C) as described above at day 10 and day 5
before used as donor mice. Recipient mice were also pretreated
with poly (I: C) followed by a whole body irradiation with 12 Gy.
The transplanted animals received antibiotic (Borgal, Schering-
Plough, Muenchen-Neuperlach, Germany) containing drinking
water for 14 days.
To trace transplanted BM cells, we generated gp130
DMxSTAT
and gp130
DMxRas GFP-double transgenic mice. Gp130
DMxSTAT
mice were generated by breeding MxCre gp130
loxP/loxP with
gp130
DSTAT/DSTAT knockin mice expressing a truncated gp130
knockin allele that lacks the essential region for the activation of
STAT1 and-3 signalling [9] [14–15]. Gp130
DMxRas mice were
generated by crossing MxCre gp130
loxP/loxP with gp130
Y757F/
Y757F knockin mice, which express a gp130 allele carrying a point
mutation at tyrosine Y757 thus being defective in Ras-signalling.
The genotypes were analysed by PCR for MxCre, gp130
loxP/loxP,
gp130
Y757F and the gp130
DSTAT allele as described previously




DSTAT in conjunction with b-actin/GFP
respectively.
A cartoon of the different signalling pathways is displayed in
Figure S1A.
Isolation of cells and flow cytometry
White blood cells (WBC) were counted automatically using an
automated cell counter (Hereus, Karlsruhe Germany). After red
blood cell lysis (PharmLyse, BD Biosciences, Heidelberg, Ger-
many) cells were stained for CD45, CD11b, CD19, CD4 and CD8
(all eBiosciences, Frankfurt, Germany) and subjected to flow
cytometry using a BD Canto II (BD Biosciences, Heidelberg,
Germany). Data were analysed using FlowJo software (TreeStar,
Ashland, USA).
An example flow cytometry plot for a GFP negative donor
mouse (upper graph) as well as for a GFP positive donor animal
(lower graph) is shown in Figure S1B. In order to study the
absolute numbers of different cell populations, percentages of
GFP+ fractions were multiplied with the total number of
leucocytes.
Data of donor mice of all different genotypes at 8 weeks of age
as well as pI; pC induced donor mice as comparison to
transplanted mice is presented in Figure S2A–G.
In vitro stimulation of freshly isolated BM cells






DMxSTAT mice were stimulated with
recombinant IL-6 (100 mg/ml) for 2 and 6 hours. Western Blot
analysis was performed for unstimulated (control) and stimulated
cells.
SDS Page and Western Blot
For primary antibody incubation, membranes were probed with
anti-phospho-STAT-3 (Tyr705; #9131s; Cell Signalling, Frank-
furt, Germany) and anti-GAPDH (4699–9555, Poole, Dorset, UK)
antibodies. As a secondary antibody, HRP-linked anti-rabbit
immunoglobulin G (#7074; Cell Signaling, Frankfurt, Germany)
and HRP-linked anti-mouse immunoglobulin G (sc-2005, Santa
Cruz, Heidelberg, Germany) were used. The antigen-antibody
complexes were visualised using the ECL Chemiluminescence Kit
(GE Healthcare, Buckinghamshire, England).
Statistics
All numerical results are expressed as mean +/2 SE and
represent data from at least 5 animals per time point. All
significant p-values were measured by student’s T-test. A value of
p,0.05 was considered significant (* = p,0.05, ** = p,0.01,
Gp130 Signaling during Bone Marrow Transplantation
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by a Mantel-Cox test in GraphPad Prism).
Results
Gp130 in donor cells is required for optimal engraftment
after BM transplantation (BMT)
In order to analyse the functional role of gp130 during the
process of BMT, lethally irradiated recipient mice received
unfractionated GFP(+)gp130
loxP/loxP (gp130 competent – func-
tionally equivalent to wildtype) or GFP(+)gp130
DMx (gp130-
deficient) BM cells. The engraftment of transplanted (donor
derived = GFP+) cells was analysed by determining the relative
number of GFP+ cells in recipient animals. Recipients of
gp130
DMx BM showed significantly lower total white blood cell
counts 2 and 4 weeks after BM transplantation compared to
recipients that were transplanted with gp130
loxP/loxP BM
(Figure 1A). Analysis of the CD45(+) cell fraction of GFP(+) cells
after transplantation proved the delayed engraftment of gp130
DMx
BM in gp130
loxP/loxP recipients (Figure 1B, C and Figure S3A).
Interestingly, total white blood cell counts after BM reconstitution
was independent of the recipients’ gp130 status, meaning that
gp130
DMx or recipients receiving wildtype (gp130
loxP/loxP)o r
gp130-deficient (gp130
DMx) BM had equal WBC numbers after
BMT (Figure S4A, B). Therefore, throughout the following
experiments we focused on gp130-functions in the haematopoietic
donor cells and used only gp130
loxP/loxP recipients.
Gp130
loxP/loxP mice that were transplanted with gp130
loxP/loxP
BM showed no change in platelet counts (around 600–800 G/l) as
compared to untreated wildtype animals (Figure S2C). In contrast,
recipients of gp130
DMx donor BM had significantly less platelets
(about 300 G/l) two weeks after BMT (Figure 1D). Additional
analysis of haemoglobin values showed a relative temporary
anaemia in recipients of gp130
DMx BM (Figure 1E).
Lymphocyte and myeloid cell development after BMT
requires intact gp130 signalling in donor cells
Next, we delineated the effects of gp130-signals on immune cell
development and differentiation. First, we investigated the de-
velopment of mature T-cells. Interestingly, we found significantly
reduced numbers of CD4(+)/GFP(+) and CD8(+)/GFP(+) T-cells
two and four weeks after transplantation of gp130
DMx BM,
compared to transplantation of gp130
loxP/loxP cells (Figure 2A, B
and Figure S3B, C), demonstrating a severely impaired T-cell
development in the absence of functional gp130 in haematopoietic
progenitors.
To investigate the engraftment of B-cells we analysed CD19(+)/
GFP(+) cell frequencies and numbers. Recipients that were
transplanted with gp130
loxP/loxP BM had robust B-cell numbers
(2–2.5 G/l), which is comparable to untreated animals (Figur-
e S2F). In contrast, mice receiving gp130
DMx BM showed
significantly reduced CD19(+)/GFP(+) B-cells for up to week 4
after transplantation (Figure 2C, D and Figure S3D).
As a marker of myeloid cell development we measured
CD11b(+)GFP(+) cells numbers. Interestingly, 2 weeks after
BMT we could detect significantly lower CD11b(+) numbers in
mice that received gp130
DMx BM compared to gp130
loxP/loxP
donors (Figure 2E, F and Figure S3E), suggesting that gp130-
signalling is also involved in the engraftment and proliferation of
this lineage.
Overall, this lineage specific analysis revealed a pan-leukocyte
development and/or engraftment blockade of gp130-deficient BM
grafts.
Differential role of gp130-STAT1/3 and gp130-Ras signals
during BM engraftment
Intracellular signalling induced by IL-6/gp130 leads to the
activation of the JAK/STAT and Ras-pathway. To further
evaluate the exact contribution of either pathway in the process
of BM transplantation, mice with deficient Ras (gp130
DMxRas)o r
STAT (gp130
DMxSTAT) signalling were used as BM donors.
Recipient gp130
loxP/loxP mice were analysed 2, 4 and 6 weeks
after BM transplantation according to the previous experiments.
First, total leukocyte cell counts were determined at different
time points after BMT. Interestingly, two and four weeks after BM
transplantation mice transplanted with gp130
DMxSTAT BM dis-
played very low levels of total white blood cells whereas animals
transplanted with gp130
DMxRas BM showed comparable cell
numbers as recipients of gp130
loxP/loxP BM (Figure 3A). If
anything, gp130
DMxRas BM reconstituted mice showed enhanced
WBC recovery. This observation is in line with previously reported
over-activation of STAT3 in gp130
DMxRas cells [9,10] (Figure S5).
The delayed engraftment of gp130
DMxSTAT BM could be
corroborated by analysing CD45(+)GFP(+) cells. Mice trans-
planted with gp130
DMxSTAT BM displayed less CD45(+)GFP(+)
cells than recipients of gp130
DMxRas or gp130
DMx BM (Figure 3B).
In contrast to WBC, whose development strongly depended on
gp130-STAT1/3 signalling, we found significantly lower platelet
counts in animals that were transplanted with either gp130
DMxRas
or GFP(+)gp130
DMxSTAT BM after 2 weeks. Recipients of
gp130
DMxRas cells displayed a temporarily aggravated thrombo-
cytopenia (Figure 3C). Thus, in contrast to leucopoiesis, which
requires gp130-STAT1/3 activation, early thrombopoiesis is
mediated by gp130-Ras signals.
To complete our blood count analysis, we analysed hemoglobin
values after BMT and observed a significant, albeit mild anemia in
gp130
DMx and gp130
DMxSTAT BM transplanted mice compared to
recipients of wildtype cells 4 weeks after BMT (Figure 3D).
Gp130/STAT-signalling controls development of CD4(+),
CD8(+) and CD19(+) cells
Given the central role for gp130 for CD4(+) and CD8(+), T cell,
CD19(+) B cell and CD11b(+) myeloid cell development after
BMT (Figure 2, Figure S3), we next aimed to delineate the
responsible gp130-dependent intracellular signalling pathways in
donor cells. In line with the observed gp130-STAT1/3-de-
pendency of WBC recovery after BMT, we found that mice
transplanted with gp130
DMxSTAT BM showed the similarly
reduced numbers of CD4(+)/GFP(+), CD8(+)/GFP(+),
CD11b(+)/GFP(+) and CD19(+)GFP(+) cells as mice transplanted
with complete gp130 deficient (gp130
DMx) BM (Figure 4A-D). In
contrast, animals receiving gp130
DMxRas BM showed CD4(+)/
GFP(+) and CD(8+)/GFP(+) cell numbers comparable to those of
recipients of gp130
loxP/loxP BM (Figure 4A, B). Of note, two weeks
after BMT B-cell engraftment and proliferation as determined by
CD19(+)/GFP(+)cells was significantly delayed in both
gp130
DMxSTAT and gp130
DMxRas donor groups (Figure 4C).
Recovery however was significantly faster in mice receiving
gp130
DMxRas BM. The most striking phenotype was observed for
CD11b(+) cell recovery. Here, gp130- and gp130-STAT1/3
deficiency delayed engraftment, whereas gp130
DMxRas donor cells
displayed a strikingly overshooting response with up to five-fold
increase in circulating CD11b(+)GFP+(+) numbers compared to
all other groups (Figure 4D). This result indicates, that while
gp130-STAT1/3 signalling is not absolutely required for engraft-
ment of CD11b(+) cells, its overactivation (as observed in
Gp130 Signaling during Bone Marrow Transplantation
PLoS ONE | www.plosone.org 3 June 2012 | Volume 7 | Issue 6 | e39728Figure 1. Delayed engraftment of gp130
DMx donor BM in the early phase after BM transplantation (BMT). Numbers of total white blood
cells (WBC) [G/l] after BMT: Displayed are total white blood cell counts after BM transplantation at the indicated time points (2, 4, 6 weeks). Less total
white blood cells can be detected in gp130
loxP/loxP mice that were transplanted with GFP(+)gp130
DMx BM compared to GFP(+)gp130
loxP/loxP donor
mice. A) Engraftment of CD45(+)GFP(+) white blood cells (WBC) [G/l] after BMT: Displayed is an example flow cytometry plot 2 weeks after BMT of
gp130
loxPloxP BM. Gating on all white blood cells in the FSC/SSC is followed by gating on CD45+ cells. The GFP+ (donor) fraction is shown as
a histogram. B) Delayed engraftment of CD45(+)GFP(+) white blood cells (WBC) [G/l] after BMT of gp130 deficient BM: An example flow cytometry
plot 2 weeks after BMT of gp130
DMx BM is demonstrated. Gating on all white blood cells in the FSC/SSC is followed by gating on CD45+ cells. The
GFP+ (donor) fraction is shown as a histogram. Comparison to Fig. 1B shows the decreased GFP+, donor derived, cell fraction. C) Gp130 deficiency in
donor mice leads to thrombocytopenia: Depicted are the platelet counts 2, 4 and 6 weeks after BMT. Gp130
loxP/loxP littermates that received
GFP(+)gp130
DMx BM showed a significant thrombocytopenia 2 weeks after BMT. D) Haemoglobin values [g/dl] after BM transplantation:
Haemoglobin values 2, 4 and 6 weeks after BM transplantation are depicted with a significant difference 4 weeks after BMT. [***p,0.001].
doi:10.1371/journal.pone.0039728.g001
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PLoS ONE | www.plosone.org 4 June 2012 | Volume 7 | Issue 6 | e39728Figure 2. Subgroup analysis of different T-cell subsets after BMT. A)/B) Engraftment of CD4(+)/GFP(+) and CD8(+)/GFP(+) T-cells [G/l]:
CD4(+)/GFP(+) (upper plots) and CD8(+)/GFP(+) T-cells (lower plots) were analysed by flow cytometry analysis 2, 4 and 6 weeks after BM
transplantation. A lower percentage of CD4(+)/GFP(+) and CD8(+)/GFP(+) T-cells could be detected in gp130
loxPloxP recipients that were transplanted
with GFP(+)gp130
DMx donor BM. Displayed are example flow cytometry plots for a recipient mouse of wildtype donor BM (A) as well as for a recipient
animal of gp130 deficient BM (B) 2 weeks after BMT. C)/D) Engraftment of CD19(+)/GFP(+) B-cells [G/l]: CD19(+)/GFP(+) B-cells derived from
GFP(+)gp130
DMx donor BM (Fig. 2D) engrafted decelerated compared to GFP(+)gp130
loxPloxP donor BM (Fig. 2C) 2 and 4 weeks after BM
transplantation. Shown are example flow cytometry plots 2 weeks after BMT. E)/F) Engraftment of CD11b(+)/GFP(+) cells [G/l]: 2 weeks after BM
transplantation the percentage of CD11b(+)/GFP(+) cells was lower in gp130
loxP/loxP recipients transplanted with GFP(+)gp130
DMx donor BM
Gp130 Signaling during Bone Marrow Transplantation
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DMxRas cells, Figure S2) represents a very potent stimulus for
myelopoiesis after BMT.
Gp130 dependent STAT-signalling in transplanted cells is
essential for survival after BMT
To unravel whether the differences in gp130 dependent
intracellular signalling during cellular engraftment represent
a limiting step for BMT we performed a survival analysis. To
this end we determined the critical threshold for host survival by
transplanting decreasing numbers of BM cells into lethally
irradiated animals (Fig. 5). Whereas transplantation of 10
6
unfractionated donor cells resulted in 100% survival – regardless
of donor BM genotype (Figure 5A), 2610
5 donor cells induced
25% mortality solely in the group of gp130
DMxSTAT donors
(Figure 5B). Finally, we further reduced the number of
compared to controls. Displayed are example flow cytometry plots for 2 weeks transplanted mice having received wildtype (E) or gp130 deficient (F)
BM respectively.
doi:10.1371/journal.pone.0039728.g002
Figure 3. Dissection of intracellular gp130 signalling pathways. A) Number of total white blood cells (WBC) [G/l] after BMT: Displayed are the
total white blood cell counts after BM transplantation at the indicated time points (2, 4 and 6 weeks). Less total white blood cells could be detected in
gp130
loxP/loxP mice that were transplanted with GFP(+)gp130
DMxSTAT BM. Transplantation of GFP(+)gp130
DMxRas donor BM did not result in any
significant difference concerning the total WBC count. B) Delayed engraftment of CD45(+)/GFP(+) white blood cells (WBC) [G/l] after BMT is STAT-
dependent: Displayed are the CD45(+)/GFP(+) (donor derived) cells after BM transplantation at the indicated time points (2, 4 and 6 weeks). Whereas
transplantation of GFP(+)gp130
DMxRas donor BM into gp130
loxP/loxP animals did not lead to a delayed engraftment of CD45(+)/GFP(+) cells,
transplantation of gp130
DMxSTAT into gp130
loxP/loxP resulted in a significant decrease of CD45(+)/GFP(+) cells. C) Defective Ras and STAT signalling in
donor mice leads to thrombocytopenia: Depicted are the platelet counts 2, 4 and 6 weeks after BMT. Transplantation of GFP(+)gp130
DMxRas as well as
GFP(+)gp130
DMxSTAT donor BM led to a significant thrombocytopenia 2 weeks after BM transplantation. D) STAT-deficiency in donor mice leads to
anaemia after BM transplantation: Depicted are the haemoglobin values 2, 4 and 6 weeks after BM transplantation with a significant anaemia in
gp130
loxP/loxP recipients transplanted with GFP(+)gp130
DMxSTAT donor BM 4 weeks after BMT. [**p,0.01, ***p,0.001].
doi:10.1371/journal.pone.0039728.g003
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4 cells. Under these conditions,
none of the mice that received gp130
DMxSTAT cells survived BMT,
while 33% of animals receiving gp130
DMx and 75% of mice
transplanted with gp130
DMxRas survived (Figure 5C). In contrast,
survival was 100% in mice receiving gp130
loxP/loxP BM grafts
(Figure 5C).
Collectively, these data clearly indicate that gp130-STAT1/3
signals play a predominant role in donor cells after BMT,
regulating BM engraftment and importantly, controlling the
outcome of BMT.
Discussion
BMT is a clinically well-established procedure for decades.
However, a detailed understanding of underlying molecular
processes involved in stem cell engraftment and proliferation is
still incomplete. IL-6 is an important cytokine that not only
regulates the homeostasis of haematopoietic stem cells but that is
prominently involved in the control of various inflammatory
processes [18]. The latter is important especially for BMT, which
naturally comprises the need for immunosuppression, thereby
Figure 4. Subgroup analysis of different T-cell subsets after BMT. A) Engraftment of CD4(+)/GFP(+) T-cells [G/l]: CD4(+)/GFP(+) T-cells were
analysed by flow cytometry analysis 2, 4 and 6 weeks after BM transplantation. A significant lower number of CD4(+)/GFP(+) T-cells could be detected
in gp130
loxPloxP recipients that were transplanted with GFP(+)gp130
DMxSTAT donor BM. Transplantation of GFP(+)gp130
DMxRas donor BM resulted in
the same number of CD4(+)/GFP(+) T-cells as transplantation of gp130
loxP/loxP BM into gp130
loxP/loxP littermates. B) Engraftment of CD8(+)/GFP(+)T -
cells [G/l]: The absolute number of CD8(+)/GFP(+) T-cells was determined by flow cytometry analysis 2, 4 and 6 weeks after BM transplantation. The
number of CD8(+)/GFP(+) T-cells was significantly lower in wildtype mice that were transplanted with GFP(+)gp130
DMxSTAT 2 and 4 weeks after BMT.
C) Engraftment of CD19(+)/GFP(+) B-cells [G/l]: CD19(+)/GFP(+) B-cells derived from GFP(+)gp130
DMxSTAT donor BM engrafted into recipient mice with
significant differences at the 2 and 4 week time point. Gp130
loxP/loxP recipients of GFP(+)gp130
DMxRas donor BM also displayed a somewhat delayed
engraftment 2 weeks after BMT but recovered faster as shown 4 and 6 weeks after BMT. D) Engraftment of CD11b(+)/GFP(+) cells [G/l]:
Transplantation of GFP(+)gp130
DMxRas donor BM into gp130
loxP/loxP resulted in a significant increase of CD11b(+)/GFP(+) cells at all indicated time
points (2, 4, 6 weeks) after BMT. GFP(+)gp130
DMxSTAT donor BM led to the same number of CD11b(+)/GFP(+) cells as the transplantation of
GFP(+)gp130
DMx donor BM. [*p,0.05, **p,0.01].
doi:10.1371/journal.pone.0039728.g004
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conditions. Moreover, patients who finally undergo BMT have
usually been treated before with several bone marrow injuring
chemotherapeutic drugs. Due to the toxic nature of most used
therapeutics (incl. irradiation) not only the stem cell pool, but also
the microenvironment including endothelial and supporting
stromal cells in recipient’s BM is affected. Thus, subsequently
infused donor cells do not only have to combat with immunolog-
ical challenges but also with the situation of an inflamed and
structurally disintegrated stem cells niche. Interestingly, the
regulatory interleukin-6 (IL-6) pathway also seems to play an
important role during those pre-conditioning processes [19] and is
therefore of particular relevance.
Figure 5. Survival analysis after BM transplantation. A) Survival curve after BMT of 1610
6 donor cells (6 mice per group): Recipient mice of all
different donor genotypes survived BMT of 1610
6 donor cells. B) Survival curve after BMT of 2610
5 donor cells (8 mice per group): gp130
DMxSTAT
transplanted mice showed a 75% survival after BMT with 2610
5 donor cells. All the other animals survived BMT to 100%. C) Survival curve after BM
transplantation using the amount of 5610
4 donor cells (6 mice per group): Transplantation of gp130
loxP/loxP donor BM into gp130
loxP/loxP recipient
mice led to a survival rate of 100%. 75% of gp130
loxP/loxP recipients of gp130
DMxRas donor BM survived the experiment. However, if gp130
loxP/loxP
recipients were transplanted with gp130
DMx BM, they survived in 33%. Finally, transplantation of gp130
DMxSTAT donor BM led to 100% mortality with
no (0%) surviving recipient mice. [*p,0.05].
doi:10.1371/journal.pone.0039728.g005
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and STAT- signalling have been demonstrated in a number of
tissues including the liver, which as the major regulator of the
acute-phase response plays a central role in the control of innate
immune functions [20,21]. In contrast, until now, little was known
about contribution of either intracellular signalling pathway
following BMT. The aim of the current study was therefore now
to delineate gp130-Ras- and gp130-STAT-dependent pathways in
a clinically relevant in vivo mouse model of BMT.
An earlier study using mice with an endothelial cell specific
gp130-deletion using a Tie2-Cre construct, provided evidence for
a spontaneous BM dysfunction [11]. The BM of those mice was
hypocellular, while haematopoietic stem cells seemed unaffected.
As a consequence, extramedullary haematopoiesis was enhanced
under this condition. Further analysis then revealed a functional
defect in endothelial stromal cells that led to a dysfunctional
microenvironment in Tie2-Cre/gp130 mice, a phenotype that
could not be rescued by BMT. In our study we failed to detect
a delayed BM engraftment or a disturbed proliferation of any
haematopoietic cell population, if gp130
DMx mice (lacking gp130
in all cells, including endothelial cells) were used as recipients of
wildtype BM (Figure S4A, B). However, we would like to point out
that the induced gp130-knockout in BM stromal cells and
endothelial cells may have been incomplete.
In contrast, we observed a strong dependency on gp130-signals
within the transplanted BM cells. Mice receiving gp130-depleted
BM showed transient leukopenia, anaemia and thrombocytopenia
and a severely compromised survival if low cell numbers were
transferred (Figure 1, Figure 5 and Figure S3). Thus, gp130-
dependent signalling in donor cells seems to affect all BM lineages
(Figure 1, Figure 3). This is an important and novel observation
because it demonstrates that gp130-dependent gene activation is
required for proper expansion of blood progenitor cell lineage.
Notably, 6 weeks after irradiation and transplantation most
lineages were able to recover, which may be best explained by
compensatory mechanisms such as extramedullary haematopoi-
esis. Importantly, we did not observe a preferential selection of
potentially remaining non-gp130-deleted cells in the BM of
recipient mice. This could reflect that gp130 is most important
for proliferation of the rather immature BM progenitors.
Moreover, very likely there is a threshold effect of gp130, because
otherwise the transplantation of gp130-deficient BM would have
even more severe effects on survival. The second indication for
dose-dependency stems from our experiment using limited
amounts of donor cells (Figure 5). Here, recipient mice ultimately
died only if the number of transplanted cells was reduced below
a certain threshold of approximately 1610
5 cells (Figure 5B, C).
Under real life clinical conditions treatment of neoplasms – not
only hematopoietic neoplasms – and BM-failure comprises the
homeostasis of the whole organism. Both, the disease itself and the
used treatments provoke a) a local (in the BM itself) and b) an often
even systemic inflammatory environment within the affected
patient that is mediated by cytokines or growth factors. Here, IL-6
is relevant as the messenger who controls the hepatic acute phase
reaction [20]. Humoral factors secreted from bone-marrow
stromal cells as a response to chemotherapeutic drugs or biological
treatments also act paracrine on hematopoietic stem cells itself,
thereby sometimes sustaining and perpetuating the underlying
inflammatory or malignant condition [22]. Those prerequisites
make it even more important to understand the biology of bone-
marrow regeneration and involved regulating factors.
Here, we now demonstrate that cells with a deficient gp130-
STAT-signalling pathway (gp130
DMxSTAT) were acutely compro-
mised in their ability to generate effective numbers of WBCs or
CD45(+) cells, respectively (Figure 3A, B). This matches recent
studies reporting a STAT3-dependence of T-cell development in
patients with autosomal-dominant hyper-IgE syndrome (AD-
HIES) [23]. Interestingly, early thrombopoiesis seemed to require
gp130-Ras-signalling, since recipients of gp130
DMxRas BM dis-
played severe thrombocytopenia 2 weeks post BMT. Even more
striking was the observed overshooting expansion of CD11b(+)
cells after gp130
DMxRas BMT. As mentioned earlier, cells bearing
the gp130-757Y mutation (gp130
DMxRas) are known to spontane-
ously over activate the gp130-STAT3 pathway (Figure S5). Thus,
the increased amount of CD11b(+) could indicate that permanent
gp130-STAT3-activation is a potent driver of strong myelopoiesis
which has not been previously reported [9]. Therefore, gp130-
STAT3 could represent a valuable therapeutic target to treat
neutropenic conditions after BMT, although limitations exist as
discussed below.
Taken together our data now unravel differential effects of
either STAT- or Ras-dependent signalling in BM cells after
transplantation. Proper function of the STAT-signalling pathway
is most important for graft survival and its disruption can cause
severe graft failure. Data about the functionality of this pathway
under the condition of BMT in patients are very limited. It would
be of interest to determine whether patients with graft failure or
under chemotherapy display altered gp130-STAT responses that
might contribute to BM dysfunction.
Yet, there is evidence for a general importance of this signalling
cascade in the development of hematopoietic malignancies [24–
25]. Here mutations in the gp130-bound and activated JAK2-gene
– which lead to a permanent activation of the STAT pathway and
carry the potential of a subsequent malignant cell transformation –
are causally related to myeloproliferative neoplasms. This hampers
strategies intending to over stimulate the gp130 pathway with
activating therapeutics [26]. Therefore further research is neces-
sary to clarify, how eventually a timely limited and only temporary
interference with the gp130-STAT pathway might be of benefit
for BM regeneration after transplantation or chemotherapy as well
as in BM failure syndromes. Moreover, we need to get a deeper
general knowledge about the interplay of cytokines and messengers
controlling regeneration and engraftment of bone marrow at the
stromal/stem cell interface to improve therapeutic alternatives.
Supporting Information
Figure S1 A) Cartoon illustrating the used different
genotypes: In a wildtype condition, IL-6 binds to its
receptor gp80 and forms a complex with gp130 receptor
molecules. This leads to the dimerization of gp130 with its
subsequent intracellular phosphorylation. Depending on the
phosphorylated tyrosine-residue the downstream signal activates
either the STAT or Ras pathway (gp130
loxP/loxP). Gp130
DMx mice
carry a conditional gp130 knockout, with neither STAT nor Ras
signalling cascade activated. Lack of the four distal tyrosines, the




generated by crossing MxCre gp130
loxP/loxP with gp130
Y757F/
Y757F knockin mice, which express a gp130 allele carrying a point
mutation at tyrosine Y757 thus being defective in Ras-signalling.
B) Flow cytometry analysis of peripheral blood: Displayed is the
flow cytometry analysis of a GFP negative (upper histogram) and
a GFP positive (lower histogram) donor mouse. Pre-transplant flow
cytometry conditions also served as controls to determine the
threshold for GFP positivity after BMT.
(TIFF)
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subgroup analyses for untransplanted/untreated as well
as untransplanted/pI: pC treated 8 week old mice (n=5
per group). A) WBC counts for all genotypes do not show
significant differences pre-transplant. B) Haemoglobin values do
not differ significantly between different genotypes pre transplant.
C) No significant differences were detected in thrombocyte levels
pre transplant. D) CD4 T cell counts did not show significant
differences although there was a trend towards more CD4 T cells
in untreated gp130
DMxSTAT animals. E) CD8 T cells also tended to
be higher in untreated gp130
DMxSTAT mice although no significant
differences were detected. F) CD19+ B cells were lower but not
significantly decreased in all three genotype groups compared to
untreated wildtype littermates. G) CD11b+ cells were increased
without significance in untreated as well as pI: pC treted wildtype
mice compared to the knockin/knockout genotypes.
(TIFF)
Figure S3 Delayed engraftment of gp130
DMx donor BM
in the early phase after BM transplantation. A) Delayed
engraftment of CD45(+)GFP(+) white blood cells (WBC) [G/l]
after BMT: Displayed are CD45(+)GFP(+) (donor derived) cells
after BM transplantation at the indicated time points (2, 4,
6 weeks). A delay in the engraftment of GFP(+)gp130
DMx BM
transplanted into gp130
loxP/loxP can be demonstrated. B) Engraft-
ment of CD4(+)/GFP(+) T-cells [G/l]: CD4(+)/GFP(+) T-cells
were analyzed by flow cytometry analysis 2, 4 and 6 weeks after
BM transplantation. A significant lower number of CD4(+)/
GFP(+) T-cells could be detected in gp130
loxPloxP recipients that
were transplanted with GFP(+)gp130
DMx donor BM. C) Engraft-
ment of CD8(+)/GFP(+) T-cells [G/l]: The absolute number of
CD8(+)/GFP(+) T-cells was determined by flow cytometry analysis
2, 4 and 6 weeks after BM transplantation. Gp130
loxPloxP animals
that were transplanted with GFP(+)gp130
DMx donor BM displayed
significantly less CD8(+)/GFP(+) T-cells 2 and 4 weeks after BMT
compared to GFP(+)gp130
loxP/loxP donor mice. D) Engraftment of
CD19(+)/GFP(+) B-cells [G/l]: CD19(+)/GFP(+) B-cells derived
from GFP(+)gp130
DMx donor BM engrafted decelerated com-
pared to GFP(+)gp130
loxPloxP donor BM 2 and 4 weeks after BM
transplantation. E) Engraftment of CD11b(+)/GFP(+) cells [G/l]:
2 weeks after BM transplantation the number of CD11b(+)/
GFP(+) cells was significantly lower in gp130
loxP/loxP recipients
transplanted with GFP(+)gp130
DMx donor BM compared to
controls. 4 and 6 weeks after BM transplantation both groups
show a decreasing number of CD11b(+)/GFP(+) compared to the
2 week time point. [*p,0,05, **p,0,01, ***p,0,001]
(TIFF)
Figure S4 gp130 status of recipient mice does not affect
WBC engraftment after BMT. A) Numbers of total white
blood cells (WBC) [G/l] after BMT: Displayed are total white
blood cell counts after BM transplantation at the indicated time
points (2, 4, 6 weeks). No significant differences could be detected
for BMT of gp130
loxP/loxP donor BM in wildtype or gp130
deficient recipient mice. B) Engraftment of CD45(+)GFP(+) white
blood cells (WBC) [G/l] after BMT does not depend on recipient’s
gp130 status: Displayed are CD45(+)GFP(+) (donor derived) cells
after BM transplantation at the indicated time points (2, 4,
6 weeks). No significant differences could be detected for BMT of
gp130
loxP/loxP donor BM in wildtype or gp130 deficient recipient
mice.
(TIFF)
Figure S5 Mx-Cre-mediated deletion efficacy of gp130-
activation. In order to demonstrate the Mx-Cre mediated
deletion-efficacy in different mouse genotypes, we isolated BM of





DMxSTAT) after pIpC-injection. 5610
6 cells were stimulated
with recombinant IL-6 (100 mg/ml), for 2 and 6 hours. Finally,
cells were harvested from unstimulated controls as well as
stimulated BM cells and analyzed by Western Blot for STAT3-
phosphorylation. Gp130loxPloxP mice showed an increased
STAT3-phosphorylation after 2 hours, even increasing after
6 hours. In contrast, gp130
DMx littermates showed much less
phosphorylation, reflecting the abolished signalling. Gp130
DMxRas
animals displayed a hyperactivation of STAT3 after IL-6
stimulation and gp130
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